-
乳腺癌是女性恶性肿瘤患者主要的死亡原因之一[1],是城市地区女性最常见的恶性肿瘤,其发病率已居女性恶性肿瘤的首位[2]。乳腺癌常出现骨转移灶,引起一系列的症状和体征(如骨痛、病理性骨折等),严重影响患者的生活质量和生存状况。99Tcm-MDP全身骨显像发现骨病灶的灵敏度较高而特异度较低;联合MRI增强检查后能明显提高骨转移灶的早期诊断及鉴别诊断准确率[3]。SPECT/CT融合显像在提供精确的解剖定位的同时,还可显示病灶的特征性影像学改变。对鉴别诊断颅骨良恶性病变有较高的灵敏度和特异度[4]。
本研究回顾性分析了我院核医学科乳腺癌患者行SPECT/CT融合显像的临床资料,探讨SPECT/CT融合显像在诊断和鉴别全身骨显像异常放射性浓聚灶性质中的临床价值。
乳腺癌患者骨病灶SPECT/CT融合显像的临床价值
The clinical value of SPECT/CT fusion imaging in the diagnosis of bone metastasis of breast cancer
-
摘要:
目的 探讨SPECT/CT融合显像诊断与鉴别乳腺癌患者全身骨显像放射性异常浓聚灶的临床价值。 方法 对25例乳腺癌患者的99Tcm-MDP全身骨显像显示的骨异常放射性浓聚灶行SPECT/CT融合显像。4~8个月后再次行全身骨显像及SPECT/CT融合显像复查。图像由两名有经验的核医学科医师独立分析, 部分CT图像由有经验的放射科医师分析指导。 结果 在25例乳腺癌患者的37个异常放射性浓聚灶中, 确定29(29/37, 78. 38%)个病灶为骨转移灶, 其中有2个椎体病灶在初次检查中判读为良性病灶; 8(8/37, 21. 62%)个病灶为良性病灶, 其中1个肋骨病灶在初次检查中判读为骨转移灶, 比较全身骨显像和SPECT/CT融合显像, 二者之间差异有统计学意义(χ2=6.975, P < 0.05)。骨转移灶主要分布于椎骨及肋骨。全身骨显像和SPECT/CT融合显像的诊断灵敏度、特异度、阳性预测值、阴性预测值和准确率分别为82.76%、75.00%、92.31%、54.55%、81.08%和93.10%、87.50%、96.43%、77.78%、91.89%。采用受试者操作特性曲线(ROC)进行分析, 结果:全身骨显像曲线下面积为0. 860±0. 056, SPECT/CT融合显像曲线下面积为0. 974±0. 020。SPECT/CT融合显像曲线下面积大于全身骨显像曲线下面积, 两者之间差异具有统计学意义(χ2=9. 924, P < 0.001)。 结论 SPECT/CT融合显像较全身骨显像能更好地鉴别出乳腺癌骨病灶的性质, 能够提高诊断准确率, 具有重要的临床价值; 必要时应在4~8个月后复查SPECT/CT。 -
关键词:
- 乳腺肿瘤 /
- 肿瘤转移 /
- 体层摄影术,发射型计算机,单光子 /
- 体层摄影术,X线计算机
Abstract:Objective To evaluate the clinical value of SPECT/CT fusion imaging in the diagnosis and differential diagnosis the characteristic of the whole body bone scan radioactive hot lesions in patients with breast cancer. Methods The abnormal radioactive hot lesions of whole body bone scan in 25 patients with breast cancer underwent SPECT/CT fusion imaging immediately. Another whole body bone scan and SPECT/CT fusion imaging were carried out 4 to 8 months later in all these patients. The whole body bone scan images, SPECT/CT images and fusion images were analyzed independently by two experienced nuclear medicine physicians and some of the equivocal CT images were analyzed by an experienced radiologist. Results Among all the 37 abnormal radioactive hot bone lesions, 29(29/37, 78. 38%) lesions were confirmed metastatic lesions, including 2 vertebral lesions classified as benign lesions on the basis of the first examinations data; and 8 lesions were benign, including a rib lesion classified as benign lesion according to the first examinations data. The difference between whole body bone scan and SPECT/CT examination was statistically significant(χ2=6. 975, P < 0. 05). The bone metastases are located mainly in spine and ribs. The sensitivity, specificity, positive and negative predictive values, and accuracy of whole-body bone scan and SPECT/CT fusion imaging were 82.76%, 75.00%, 92.31%, 54.55%, 81.08% and 93.10%, 87.50%, 96.43%, 77.78%, 91.89%, respectively. The area under the receiver operating characteristics curve was 0. 860±0. 056 for whole body bone scan and 0. 974±0. 020 for SPECT/CT. The area under the curve for SPECT/CT was significantly larger compared with the whole body bone scan(χ2=9. 924, P < 0. 001). Conclusions SPECT/CT fusion imaging is better than whole body bone scan alone to characterize the abnormal bone radioactive hot lesions and it can improve the accuracy of diagnosis. The patients should repeat the modality 4 to 8 months later if necessary. -
[1] Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin, 2007, 57(1): 43-66. doi: 10.3322/canjclin.57.1.43 [2] 周涛, 陈丽芬. 30岁以下乳腺癌临床病理特征及分子生物学特点分析.国际肿瘤学杂志, 2006, 33(11): 874-877. doi: 10.3760/cma.j.issn.1673-422X.2006.11.024
[3] 汤志谋, 许海富, 李明智. SPECT核素骨显像联合MRI增强成像鉴别诊断骨转移瘤100例临床观察.实用癌症杂志, 2009, 24(5): 498-500. doi: 10.3969/j.issn.1001-5930.2009.05.019
[4] 韩鹏慧, 张书旭, 葛永兵, 等. SPECT/螺旋CT融合显像鉴别诊断颅骨良恶性病变的临床价值.中国临床医学影像杂志, 2012, 23(7): 484-487. doi: 10.3969/j.issn.1008-1062.2012.07.008
[5] 李少林, 王荣福.核医学. 7版.北京:人民卫生出版社, 2008: 153.
[6] Even-Sapir E. Imaging of malignant bone involvement by morphologic, scintigraphic and hybrid modalities. J Nucl Med, 2005, 46(8): 1356-1367. [7] Horger M, Bares R. The role of single photon emission computed tomography/computed tomography in benign and malignant bone disease. Semin Nucl Med, 2006, 36(4): 286-294. [8] Sharma P, Singh H, Kumar R, et al. Bone scintigraphy in breast cancer: added value of hybrid SPECT-CT and its impact on patient management. Nucl Med Commun, 2012, 33(2): 139-147.